Antengene Corporation Limited (HKG: 6996) announced that South Korea’s National Health Insurance Service (NHIS) has approved reimbursement for a new XPOVIO (selinexor) indication. Effective March 1, 2026, XPOVIO in combination with bortezomib and dexamethasone is now covered for adult patients with multiple myeloma (MM) who have received at least one prior line of therapy. This marks the second reimbursed indication for XPOVIO in South Korea and expands Antengene’s Asia‑Pacific market access.
Reimbursement Milestone
Item
Detail
Company
Antengene Corporation Limited (HKG: 6996)
Product
XPOVIO (selinexor)
Drug Class
First‑in‑class oral selective XPO1 inhibitor
Regulatory Body
National Health Insurance Service (NHIS), South Korea
Effective Date
March 1, 2026
New Indication
XPOVIO + bortezomib + dexamethasone for MM (≥ 1 prior therapy)
Reimbursement Status
Second XPOVIO indication covered in South Korea
XPOVIO Global Footprint
Metric
Detail
Approvals
Various indications across 10 Asia‑Pacific countries/regions
Public Reimbursement
5 markets: China mainland, Taiwan, Australia, Singapore, South Korea (new)
Asia‑Pacific Reimbursement Expansion: South Korea joins China, Taiwan, Australia, and Singapore with public XPOVIO coverage, reinforcing Antengene’s regional commercial infrastructure and payer negotiation capabilities.
Multiple Myeloma Market Access: The combination reimbursement (selinexor + bortezomib + dexamethasone) addresses a large relapsed/refractory MM population in South Korea, where bortezomib is widely used and reimbursed.
XPO1 Inhibitor Differentiation: As the first‑in‑class XPO1 inhibitor, XPOVIO offers a novel nuclear export mechanism distinct from proteasome inhibitors, immunomodulatory drugs, and anti‑CD38 antibodies—supporting combination strategies and sequencing options.
Second Indication Validation:Two reimbursed indications in South Korea demonstrate clinical and economic value recognized by HTA (health technology assessment) bodies, supporting future expansion in additional Asia‑Pacific markets.
Market Context
Factor
Impact
South Korea MM Market
~ 3,000‑4,000 new MM cases annually; high unmet need in relapsed setting with limited novel mechanism options
Asia‑Pacific Reimbursement Trend
Growing acceptance of innovative oncology therapies in public health systems; Antengene’s 5/10 market coverage sets benchmark for regional biotechs
XPO1 Competitive Landscape
No direct competitors; XPOVIO’s mechanism complements existing standards of care (daratumumab, carfilzomib, lenalidomide)
Antengene Pipeline Synergy
Reimbursement success supports ongoing development of XPOVIO combinations and next‑generation XPO1 inhibitors
Forward‑Looking Statements This brief contains forward‑looking statements regarding additional market reimbursement expansions, volume growth in South Korea, and XPOVIO combination development outcomes. Actual results may differ due to risks including competitive MM therapy launches, pricing pressure, and regulatory delays in remaining Asia‑Pacific markets.-Fineline Info & Tech
By Fineline Cube 